1 in 5
cancer patients will develop brain metastases [1].
However, traditional diagnostic methods like tissue biopsy and plasma liquid biopsy may miss ctDNA signals from brain metastases.
18x higher
median CNS ctDNA signal, compared to plasma (32.7% vs 1.8% VAF) [2].
CSF detects
LiquidHALLMARK CSF is an ultrasensitive NGS test designed to detect tumor-derived ctDNA to identify resistance mutations for primary CNS tumors, leptomeningeal metastases (LM) and brain metastases (BM) in cerebrospinal fluid.
This is a prescription only test.
Available only in the USA.
LiquidHALLMARK CSF is designed to detect guideline-recommended cancer biomarkers and resistance mutations from primary and secondary CNS malignancies, such as EGFR, H3K27M, IDH1, and IDH2, which are often not found in plasma.
1.75x
more patients with actionable alterations detected in CSF than in plasma [3]
4x
more BM-positive patients detected in CSF ctDNA than in matched CSF cytology [4]
1 in 6
patients (6/36) with new resistance mutations detected in CSF compared to baseline [4]
Downloads
Specifications [5]
Single Nucleotide Variants (SNVs)
95.59%
Sensitivity
95.10%
Specificity
0.75% VAF
LOD
Insertions / Deletions (Indels)
93.59%
Sensitivity
92.31%
Specificity
0.75% VAF
LOD
at 5ng input
References:
-
Achrol A, et al. Nat Rev Dis Primers 2019; 5: https://doi.org/10.1038/s41572-018-0055-y
-
Azad T, et al. npj Prec Oncol 2024; 8(121). https://doi.org/10.1038/s41698-024-00582-1
-
Chan D, et al. Ann Oncol 2022; 33(9): S1534. DOI: 10.1016/j.annonc.2022.10.288
-
Leung J, et al. Poster Presented at ESMO Asia 2025; FPN 770P
-
Data on file